Keywords
Arrhythmia Therapy - surgical - heart failure - postoperative mortality
Introduction
Cardiac surgery in patients with severely reduced left ventricular ejection fraction
(LVEF) has become a routine procedure. Advancements in surgical therapy reduced the
operative risk and reached good outcomes.[1] Yet, impaired LVEF is associated with high perioperative and postoperative mortalities,
with arrhythmias being among the relevant causes of death. The risk of sudden cardiac
death (SCD) is especially high in the first 3 months after cardiac surgery.[1]
[2]
[3]
Nonsurgical patients with severely reduced LVEF showed an elevated risk of ventricular
tachycardias and ventricular fibrillation (VF).[4]
[5] An implantable cardioverter–defibrillator (ICD) can terminate potentially lethal
ventricular arrhythmias (VAs) and thus prevent SCD. The prophylactic implantation
of an ICD led up to 30% less mortality in nonsurgical patients with ischemic and nonischemic
cardiomyopathies.[4]
[6] Consequently, the European Society of Cardiology and the American Heart Association
recommend an ICD implantation for patients with LVEF ≤35%. The decision is made after
3 months of optimal medical therapy for congestive heart failure because an improvement
in pump function is expected.[7]
[8] A severely reduced LVEF is seen as the most important risk factor and thus a patient
may be at risk for SCD when first diagnosed with low LVEF but may cease to be at risk
after a period of cardiac regeneration via medical or surgical therapy. LVEF was seen
to increase up to 6 months after surgical revascularization.[9]
[10] In those cases, the permanent implantation of an ICD can be avoided along with potential
complications such as device infection or bleeding. Furthermore, regular, life-long
ICD device interrogations are avoided which may be beneficial for the patients' comfort
and potentially reduces health care expenditure.
To protect patients at risk before the definite decision about an ICD implantation,
a wearable cardioverter–defibrillator (WCD) can be used to terminate hemodynamically
relevant ventricular tachycardia and VF.[11]
[12] The use of a WCD is currently recommended in patients who need transient protection
from SCD.[13]
[14]
[15]
At our department, patients are routinely screened after cardiac surgery and before
discharge into rehabilitation program. Patients with LVEF ≤35% are equipped with a
WCD for 3 months to protect them from SCD after surgery. Patients with ICD infections
undergo aggregate explantation and are then discharged with a WCD until proper freedom
from infection is achieved and a reimplantation of the ICD can safely be made. The
objective of this study was to track the improvement in LVEF, the incidence of ventricular
tachyarrhythmias, and the efficacy and safety of WCDs in patients who had undergone
recent cardiac surgery.
Patients and Methods
Study Population
We included all patients who were discharged with a WCD (LifeVest Wearable Defibrillator;
Zoll, Pittsburg, Pennsylvania, United States) from the department of cardiothoracic,
transplantation, and vascular surgery. Patients with LVEF of ≤35% or those who underwent
an explantation of an existing ICD due to infection were prescribed a WCD.
Materials
The LifeVest WCD is a vest containing electrocardiogram (ECG) and shock electrodes.
A sequence of alarms is initiated in case of a detection of VA. A biphasic defibrillation
shock is delivered if the alarm is not stopped by pressing the WCD response button
on the vest. The patient will do so as long as the VA episode has no hemodynamic relevance
and does not lead to unconsciousness. The mechanism also prevents inappropriate shocks
in case of ECG misinterpretation. The device can deliver up to (…) five shocks per
VA episode. A pacing function is not included. The LifeVest records the wearing time
(based on the ECG) as well as automatically identified VA episodes, use of response
button and shocks. A detailed description of the technical features is given by Klein
et al.[16]
Data Collection
Clinical data were collected retrospectively from our institutions' electronic records.
Included in the data analyses were age, sex, type of surgery, atrial fibrillation
events, mitral valve insufficiency, extent of coronary vessel disease, and LVEF at
the time of WCD prescription and at a 3-month follow-up. ECGs of VAs, WCD shocks,
and WCD-wearing time were analyzed in the automatically recorded WCD data provided
by Zoll. The institution's ethics board approved the study.
Statistical Analyses
Clinical data were analyzed using descriptive statistics with median and interquartile
range (IQR) or mean ± standard deviation, as appropriate. Possible predictors of VAs
and WCD shocks were analyzed using chi-square and Student's t-tests in independent samples. The change in LVEF was compared by Student's t-test in paired samples. Differences in median wearing time were compared between
genders using the nonparametric Mann–Whitney's U-test. A two-sided level of significance of p < 0.05 was assumed. Statistical analyses were performed with SPSS 24.0 (IBM, Chicago,
Illinois, United States).
Results
We identified 100 patients who were discharged with a WCD after cardiac surgery between
2012 and 2017. The mean age in the patient cohort was 67 ± 10 years. Seventy-nine
patients were male and 21 were female. Fifty-eight patients had coronary artery bypass
graft (CABG) surgery of which 41 procedures were isolated coronary revascularizations.
The types of cardiac surgeries performed on the patient cohort are presented in [Table 1].
Table 1
Types of surgery
|
Type of surgery
|
Number of patients
|
|
Isolated CABG
|
41
|
|
CABG and valve
|
16
|
|
CABG and aortic
|
1
|
|
Isolated valve surgery
|
22
|
|
ICD explant
|
16
|
|
LVAD explant
|
1
|
|
Aortic surgery (isolated)
|
2
|
|
Vascular surgery
|
1
|
|
Total
|
100
|
Abbreviations: CABG, coronary artery bypass graft; ICD, implantable cardioverter–defibrillator;
LVAD, left ventricular assist device.
Thirteen patients experienced VAs of which three were defibrillated by the WCD. All
shocks were successful and no patient received inappropriate shocks by the WCD. Asystole
did not occur in any of the patients. Out of 16, 3 (18.75%) patients with ICD explantation
experienced VAs. Out of the 16, 1 (6.25%) patient received a WCD shock while having
VA. Out of 84, 10 (11.9%) patients with heart–lung-machine surgery had VA of which
2 patients (2.38%) received a WCD shock. These two patients had a severe ischemic
cardiomyopathy with a significant left main coronary artery stenosis. The patient
with WCD shock after ICD explantation was a 50-year-old woman who had received an
ICD because of a long-QT syndrome. An ECG of a WCD shock due to VF is shown in [Fig. 1]. There were 10 patients with ventricular tachycardias which were not hemodynamically
relevant and the WCD button was pressed by the patient to prevent a device shock ([Table 2]). Mean tachycardic cycle length of self-terminating VTs was 370 ± 50 milliseconds
(range: 294–420 milliseconds). Mean duration was 47.25 ± 75.35 seconds (range: 3.12–199.52
seconds). An ECG of a self-terminating VT as recorded by the WCD is shown in [Fig. 2]. The majority of patients had ischemic cardiomyopathy, most of them had coronary
artery disease and some of them combined with valvular diseases. One patient had only
valvular heart disease and two patients were treated with ICD explantation due to
device infection. An ICD was implanted in 25 patients after the wearing period of
the WCD. The majority received a reimplantation of the ICD after infection-related
explantation: out of 16 patients with ICD explantation as primary surgery, 12 received
a reimplantation after being prescribed with a WCD (75%). Of the four remaining patients,
two had no preventive indication anymore and thus were not reimplanted. Two patients
decided against reimplantation after the follow-up period.
Fig. 1 Treatment of ventricular fibrillation.
Fig. 2 Self-terminating ventricular tachycardia.
Table 2
Patients with ventricular tachycardias
|
Patient
|
Sex
|
Age
|
Surgery
|
CM
|
LVEF (%)
|
CAD
|
Time to VT (d)
|
|
1
|
Male
|
63
|
MVR + CABG
|
ICM
|
15
|
CAD-3
|
105
|
|
2
|
Male
|
76
|
CABG
|
ICM
|
25
|
CAD-3
|
32
|
|
3
|
Male
|
78
|
CABG
|
ICM
|
30
|
CAD-3
|
78
|
|
4
|
Male
|
48
|
CABG
|
ICM
|
30
|
CAD-3
|
16
|
|
5
|
Male
|
77
|
AVR + CABG + Maze
|
ICM
|
25
|
CAD-3
|
11
|
|
6
|
Male
|
63
|
CABG
|
ICM
|
20
|
CAD-3
|
34
|
|
7
|
Male
|
57
|
MVR + CABG
|
ICM
|
20
|
CAD-2
|
15
|
|
8
|
Male
|
50
|
AVR + TVR + ASD
|
DCM
|
30
|
No
|
11
|
|
9
|
Male
|
77
|
ICD explant (infection)
|
DCM
|
25
|
No
|
5
|
|
10
|
Male
|
68
|
ICD explant (infection)
|
ICM
|
35–40
|
CAD-1
|
20
|
Abbreviations: ASD, atrial septal defect closure; AVR, aortic valve replacement; CABG,
coronary artery bypass graft; CAD, coronary artery disease; CAD-3, three-vessel coronary
artery disease; CM, cardiomyopathy; DCM, dilated cardiomyopathy; ICD, implantable
cardioverter–defibrillator; ICM, ischemic cardiomyopathy; LMCA, left main coronary
artery stenosis; MVR, mitral valve replacement; TVR, tricuspid valve reconstruction;
VT, ventricular tachycardia.
Note: Time to VT, days from date of surgery.
The median time to WCD shock was 21 days (IQR: 10–50). The patients who received a
WCD shock are presented in [Table 3]. The median time to the first episode of ventricular tachycardia was 19 days (IQR:
12–52).
Table 3
WCD defibrillated patients
|
Patient
|
Sex
|
Age
|
Surgery
|
CM
|
LVEF (%)
|
CAD
|
Time to shock (d)
|
|
1
|
Male
|
79
|
CABG
|
ICM
|
25–30
|
LMCA, CAD-3
|
21
|
|
2
|
Male
|
80
|
CABG
|
ICM
|
20
|
LMCA
|
70
|
|
3
|
Female
|
50
|
ICD explant (infection)
|
Long-QT
|
55
|
No
|
21
|
Abbreviations: AVR, aortic valve replacement; CABG, coronary artery bypass graft;
CAD, coronary artery disease; CAD-3, three-vessel coronary artery disease; CM, cardiomyopathy;
ICD, implantable cardioverter–defibrillator; ICM, ischemic cardiomyopathy; LMCA, left
main coronary artery stenosis; WCD, wearable cardioverter–defibrillator.
Note: Time to shock, days from date of surgery.
The median wearing period was 60 days (IQR: 28–95), median time to echocardiographic
follow-up of LVEF was 98 days (IQR: 55–106). Wearing time per day in our patient cohort
was almost all day with a median of 23.5 hours per day (IQR: 21.4–23.8). There was
no difference in the wearing time per day between male and female patients (p = 0.587).
At the follow-up echocardiography, LVEF significantly improved compared with the postsurgery
measurement. LVEF was 28.9 ± 8% after surgery, and at the follow-up, showed a mean
LVEF of 36.7 ± 11% (p < 0.001). The mean change in LVEF was 7.8% (95% confidence interval [CI]: 4.3–11.4,
p < 0.001). Subgroup analysis showed a significantly higher improvement in LVEF in
isolated valve surgeries compared with other types of surgeries, with a mean improvement
of +11.98% (95% CI: 3.99–19.96, p = 0.004). Patients with ICD explantation had a nonsignificant decrease in LVEF.
There was no significant difference in the occurrence of VT or VF in the type of surgical
procedure. Three-vessel disease, left main coronary artery stenosis, mitral regurgitation,
and atrial fibrillation were not significant factors for the occurrence of VAs or
WCD shocks. After the wearing period of the WCD, an ICD was implanted in 25 patients.
Eight revascularized patients out of the 58 revascularization surgeries needed a permanent
ICD (13.8% of the revascularization subgroup) and 5 patients with valve surgery out
of 22 were provided permanently with an ICD (22.7% of the valve-only subgroup).
Discussion
A WCD is prescribed for patients with elevated risk for tachyarrhythmias. This includes
patients with LVEF ≤35% with the potential to improve cardiac function and patients
with other temporary risks for tachyarrhythmias without an ICD.
We present the findings of our single-center experience from WCD patients after cardiac
surgery. The daily wearing time was 23.5 hours which shows a high level of acceptance
despite recent sternotomy and partial wound healing still in progress. Anatomic differences
in male and female patients might have disturbed wearing comfort but a gender-specific
difference in wearing time could not be seen (p = 0.587). Our results show that the cardiac pump function after surgery was severely
impaired (LVEF 28.9%), and at the follow-up, improved above the threshold for an ICD
indication (LVEF 36.7%, p < 0.001). The subgroup analysis showed significant improvements in LVEF for patients
with CABG as well as for valvular surgeries. Patients with ICD explantation declined
in their LVEF during the 3-month period of WCD ([Fig. 3]). This may be attributed to a longer history of cardiac disease. In comparison to
surgical revascularization or valve replacement, a functional improvement is not the
aim of the operation. A permanent ICD implantation after WCD was performed in 25 patients.
In 12 patients, ICD explantation due to infection was the primary surgery before WCD.
Eight revascularized patients out of the 58 revascularization surgeries needed a permanent
ICD (13.8% of the revascularization subgroup) and 5 patients with valve surgery out
of 22 were provided permanently with an ICD (22.7% of the valve-only subgroup). This
shows a rather low rate of permanent device implantation although directly after surgery
100 patients were identified as “at risk” for VAs and thus SCD. A substantial proportion
of our patients (13%) experienced ventricular tachyarrhythmias and 3% of all patients
received appropriate WCD shocks in 3 months postoperatively. Ventricular tachyarrhythmias
occurred within 5 to 105 days after surgery, most of them during the first 40 days
postoperatively. In the light of 3% VF and therefore potentially fatal arrhythmic
events, should it be considered to implant an ICD directly before discharge? In patients
with ICD explantation due to infection, we try to avoid a timely insertion of implants
to prevent reinfections. A protection through WCD has been successful in other institutions.[17]
[18] Patients with CABG or valve surgery significantly improved in their LVEF and therefore
ceased to be at risk after a 3-month period of protection through the WCD. An immediate
implantation of an ICD would be unnecessary for a relevant part. This finding is consistent
with studies for nonsurgical patients with WCD who were treated medically.[19] Avoiding the permanent implantation of an ICD will also prevent possible surgical
complications, such as device infections, low battery-related replacement or bleedings,
as well as life-long ICD interrogations. This may place less strain on the health
care system. We consider the WCD an effective tool in patients with ICD explantation
or in those patients with transient risk of experiencing VA. This may save patients
from SCD and allow a quicker discharge into a rehabilitation program as proposed by
several authors.[20]
[21] An alternative might be a prolonged hospital stay for telemetry and intensive care
monitoring due to possible VAs. This may not only slow the patient's progression of
physical activity after surgery but also cost valuable resources of the medical care
system.
Fig. 3 LVEF in % at discharge and follow-up. CABG, coronary artery bypass graft; ICD, implantable
cardioverter–defibrillator; LVEF, left ventricular ejection fraction; SD, standard
deviation.
In conclusion, the main findings of this study are that (1) WCDs were a safe and effective
therapy after cardiac surgery, (2) 13% of patients discharged with WCD had tachyarrhythmias
and 3% of all patients received a successful WCD shock, and (3) LVEF improved significantly
in our cohort, and thus, an ICD implantation could often be avoided.
